Chest ACCP Career Connection
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cook, W.
Right arrow Articles by Wooten, S.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Cook, W.
Right arrow Articles by Wooten, S.

Chest, Vol 96, 262-266, Copyright © 1989 by American College of Chest Physicians

ARTICLES

Indices of severity of obstructive sleep apnea syndrome do not change during medroxyprogesterone acetate therapy

WR Cook, JJ Benich and SA Wooten
Department of Medicine, Medical University of South Carolina, Charleston.

Medroxyprogesterone acetate (MPA) could change the frequency and/or duration of disordered breathing events (DBEs) in patients with the obstructive sleep apnea (OSA) syndrome by altering pharyngeal muscle function relative to diaphragm and external intercostal function. Ten male patients with OSA syndrome underwent an initial polysomnogram with monitoring of EEG, EOG, myohyoid EMG, oral and nasal airflow, abdominal and thoracic movement, and SaO2. The patients were then entered into a randomized, double-blind crossover study using MPA, 150 mg/day, and MPA placebo. Each patient took tablets for one week and then had a second polysomnogram. After a three week washout, the patient again took tablets for a week prior to the third and final sleep study. There was no significant difference between drug and placebo for DBE time (expressed as a percentage of sleep time), DBE frequency, DBE mean duration or mean fall in O2 saturation during DBEs. We conclude that treatment with MPA does not alter indices of severity of the OSA syndrome.


This article has been cited by other articles:


Home page
 ThoraxHome page
C F Ryan
Sleep {middle dot} 9: An approach to treatment of obstructive sleep apnoea/hypopnoea syndrome including upper airway surgery
Thorax, July 1, 2005; 60(7): 595 - 604.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
D. W. HUDGEL and S. THANAKITCHARU
Pharmacologic Treatment of Sleep-disordered Breathing
Am. J. Respir. Crit. Care Med., September 1, 1998; 158(3): 691 - 699.
[Abstract] [Full Text] [PDF]

Home page
 J. Appl. Physiol.Home page
R. M. Popovic and D. P. White
Upper airway muscle activity in normal women: influence of hormonal status
J Appl Physiol, March 1, 1998; 84(3): 1055 - 1062.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1989 by the American College of Chest Physicians.